The estimated Net Worth of Public Equities, L.P.Artal ... is at least $25.2 Milione dollars as of 1 February 2021. Public Artal owns over 252,545 units of Seer stock worth over $8,997,269 and over the last 4 years Public sold SEER stock worth over $16,200,762.
Public has made over 1 trades of the Seer stock since 2021, according to the Form 4 filled with the SEC. Most recently Public sold 252,545 units of SEER stock worth $16,200,762 on 1 February 2021.
The largest trade Public's ever made was selling 252,545 units of Seer stock on 1 February 2021 worth over $16,200,762. On average, Public trades about 252,545 units every 0 days since 2021. As of 1 February 2021 Public still owns at least 5,588,366 units of Seer stock.
You can see the complete history of Public Artal stock trades at the bottom of the page.
Over the last 7 years, insiders at Seer have traded over $150,878,393 worth of Seer stock and bought 1,798,420 units worth $33,507,980 . The most active insiders traders include Omid Farokhzad, Terrance Mcguire e Growth Fund Limited Partner.... On average, Seer executives and independent directors trade stock every 60 days with the average trade being worth of $227,813. The most recent stock trade was executed by Dipchand Nishar on 14 June 2024, trading 12,109 units of SEER stock currently worth $21,554.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Seer executives and other stock owners filed with the SEC include: